Navigation Links
Oncolytics(R) Biotech Inc. Announces Issuance of 33rd U.S. Patent
Date:10/27/2009

CALGARY, Oct. 27 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) ("Oncolytics") today announced that it has been granted its 33rd U.S. Patent, # 7,608,257, entitled "Sensitization of Chemotherapeutic Agent Resistant Neoplastic Cells With a Virus." The patent claims cover methods of using reovirus in combination with currently approved chemotherapeutic agents to treat patients that are refractory to those chemotherapeutic agents alone.

"This patent supports our expanding clinical program, including our first Phase III study, looking at REOLYSIN(R) in combination with a range of chemotherapeutic agents," said Mary Ann Dillahunty, Vice President of Intellectual Property for Oncolytics. "Many of our studies enroll patients that did not previously respond to chemotherapy, including our Phase III study in patients with platinum refractory head and neck cancers."

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of human trials including a Phase III trial in head and neck cancers using REOLYSIN(R), its proprietary formulation of the human reovirus. For further information about Oncolytics, please visit: www.oncolyticsbiotech.com.

This news release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including among others, the Company's belief as to the importance of the issuance of this patent, the safety and efficacy of the reovirus, the Company's expectations as to the potential applications of the patented technology and other statements relating to anticipated developments in th
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Oncolytics(R) Biotech Inc. Completes Patient Enrolment in U.S. Phase 2 Sarcoma Study
2. Syngenta Ventures Invests in U.S. Biotech Company Metabolon
3. Champions Biotechnology Expands Collaboration to Test Oncology Therapeutic in Biomerk Tumorgrafts(TM)
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO Investor Forum 2009
5. Pulmo BioTech Inc. Announces Cash Details of its Previously Announced Letter of Intent Intended to Bring its Pulmonary Vascular Diagnostic Product Candidate PulmoBind(TM) to the European Market
6. Monsanto and Huazhong Agricultural University Enter Into Collaboration Focusing on Development of Plant Biotechnology
7. Oncolytics Biotech(R) Inc. Announces Investment in Private Biotechnology Company
8. Epeius Biotechnologies to Partner at BIO Investor Forum
9. Reportlinker Adds Global Top 10 Biotechnology Companies -- Industry, Financial and SWOT Analysis
10. Sosei Announces Deal With UK Biotech Company
11. Media Advisory - Oncolytics Biotech(R) Inc. to Present at BioPartnering Europe
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... N.C. , Sept. 17, 2014  The In ... topics that will be featured at the conference, which ... Center on December 3 and 4, 2014. Researchers, students, ... invited to hear the following: KEYNOTE ... San Diego Skaggs School of Pharmacy ...
(Date:9/17/2014)... Shimadzu Scientific Instruments introduces ... which offers a powerful separation method for ... provides a new level of knowledge and ... to scientists analyzing pharmaceutical impurities, proteins, lipids, ... Comprehensive 2D-LC combines two independent separation modes ...
(Date:9/17/2014)... 2014 A biodegradable polymer can ... as bacteria, fungi, and algae into smaller units ... inorganic compounds, carbon dioxide, and humus in a ... and improved costs, biodegradable polymers are proving to ... to conventional polymers. Primary factors that are responsible ...
(Date:9/17/2014)... , Sept. 17, 2014 BioClinica®, Inc., a ... Solutions, today announced three of its experts are speaking ... Clinical Data Management to be held September 28 to ... . The Company also announced the innovative Compass ... quality in clinical trials acquired earlier this year, is ...
Breaking Biology Technology:In Silico Drug Discovery Conference Announces Speakers and Topics 2In Silico Drug Discovery Conference Announces Speakers and Topics 3In Silico Drug Discovery Conference Announces Speakers and Topics 4In Silico Drug Discovery Conference Announces Speakers and Topics 5In Silico Drug Discovery Conference Announces Speakers and Topics 6In Silico Drug Discovery Conference Announces Speakers and Topics 7Shimadzu’s New Nexera-e Two Dimensional Comprehensive Liquid Chromatograph Empowers Laboratories to Separate Even the Most Complex Mixtures 2Growing Demand for Eco-Friendly Products Drives the Global Biodegradable Polymers Market, According to New Report by Global Industry Analysts, Inc. 2Growing Demand for Eco-Friendly Products Drives the Global Biodegradable Polymers Market, According to New Report by Global Industry Analysts, Inc. 3BioClinica to Present at 20th Annual SCDM Conference 2BioClinica to Present at 20th Annual SCDM Conference 3
... N.J., Sept. 22, 2011 Parent ... in the United States focused on finding a cure for ... awarded Tejvir S. Khurana, MD, PhD, Professor of Physiology at ... Duchenne Grant for $98,000. (Logo: http://photos.prnewswire.com/prnh/20100119/DC39975LOGO ...
... PrimeraDx today announced that Albert Luderer has been appointed ... CEO Matthew McManus commented:  "We are excited to have Al ... launched the ICE Plex System, which is the first ... qPCR, and Al brings many years of experience in the ...
... Neogen Corporation (NASDAQ: NEOG ) has developed ... considered by many to be the most potent, naturally-occurring carcinogen. ... wide range of commodities, including corn. Because it is a ... 100 countries have established regulatory limits for aflatoxin in commodities ...
Cached Biology Technology:Parent Project Muscular Dystrophy Awards End Duchenne Grant to University of Pennsylvania's Dr. Tejvir S. Khurana 2Parent Project Muscular Dystrophy Awards End Duchenne Grant to University of Pennsylvania's Dr. Tejvir S. Khurana 3PrimeraDx Appoints Albert A. Luderer to its Board of Directors 2Neogen Launches Fully Quantitative Lateral Flow Test for Aflatoxin 2
(Date:9/17/2014)... human retinoblastoma protein gene are a leading cause of ... to fruit fly eyes to unlock the secrets of ... featured on the cover of the current issue of ... University researchers provide the first detailed examination of a ... human cancer gene, said Irina Pushel, MSU undergraduate and ...
(Date:9/17/2014)... University] After decades of decline, grasses have returned ... the eye, the marsh in those places seems healthy ... key service of the marsh coastal protection ... the ecosystem function hasn,t come back," said ecologist Mark ... of the study in the journal Biological Conservation ...
(Date:9/17/2014)... social behavior by studying nonhuman mammals and primates, but ... their unusually large brains relative to their body size ... environment---not merely in a large population of cooperating creatures, ... setting of alliances and competitors. The same is true ... social carnivores, like hyenas and lions. , A new ...
Breaking Biology News(10 mins):Abnormal properties of cancer protein revealed in fly eyes 2Cape Cod saltmarsh recovery looks good, falls short 2Cape Cod saltmarsh recovery looks good, falls short 3Being social: Learning from the behavior of birds 2
... deadline for the European Congress on Osteoporosis & Osteoarthritis ... Thursday January 17, 2013. SUBMIT YOUR ABSTRACT ... yet registered?, Register now for Europe,s largest and most ... April 17-20, 2013. Featuring renowned speakers, ...
... With $14 million from the William & Nancy ... of Orange County, UC Irvine is helping lead the ... 88 children in the U.S. autism., The funding ... Southern California, which will provide unparalleled access to assessment, ...
... ornamental fish industry faces a global problem with antibiotic ... for fish diseases may not work when needed ... antibiotic-resistant bacteria. The risk to humans is probably ... compromised immune systems, researchers said, although transmission of disease ...
Cached Biology News:UCI research turns the corner on autism 2UCI research turns the corner on autism 3Ornamental fish industry faces increasing problems with antibiotic resistance 2Ornamental fish industry faces increasing problems with antibiotic resistance 3
Viral CMV UL146/vCXC1 Biotinylated Affinity Purified PAb...
D-biotin *50 mM aqueous solution* Secondary Detection Biotin–Avidin Detection Reagents Other...
Green Standard is fluorescein....
Human/Mouse/Rat LAR Affinity Purified PAb...
Biology Products: